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Introduction
Rising Stars: Recognizing Important New
Voices in Law, Medicine, Science &
Technology
Michele B. Goodwin*
In this special issue, important new voices in law,
medicine, science, and technology comment on critical issues of
national and international significance. They are the rising
stars, applying sophisticated, interdisciplinary approaches to
important policy matters that consume our courts, legislatures,
and imaginations. The scholars participating in our invitation
only special issue are among the most talented junior scholars
in the academy
Their collective works on privacy, reproductive technology,
global health, the rise and challenges of contemporary
biotechnologies, and what these issues mean for important
stakeholders: the public, government, and business, offer
refreshing, nuanced analytical probes into murky arenas,
which are made all the more complicated by biotechnologies
outpacing of the development of laws to regulate or harness
their reach. The scholars participating in this important project
for the Minnesota Journal of Law, Science & Technology were
not given a specific charge. Rather, they were provided open
canvasses and encouraged to paint in broad, open strokes.
Their art provides revelatory insights with shared and often
cautionary themes.
Collectively, their wisdom reminds us about the
importance of foundational values across the multiple spheres
of biotechnology and its engagement in our lives, whether
through assisted reproduction—its risks, challenges, and
 2010 Michele B. Goodwin.
* Everett Fraser Professor of Law and Professor of Medicine and Public
Health, University of Minnesota.
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rewards—or in the regulation and monitoring of science and
those who conduct it, lest patients and the most vulnerable
become the unwitting victims of biological mining and genetic
exploitation.
An interesting thematic link between their works is the
cautionary note about unbridled technology and the importance
of rules of law and the roles of law. Unlike their predecessors’
generations, these scholars observe that sophisticated
biomedical technologies are more accessible to a broader group
of citizens than ever before. But with accessibility come
economic, political, and social realities, pressures, and
responsibilities, particularly when the subjects of the
technology are people, and the building blocks of life or
reproductive technology are intimately associated with their
bodies. These scholars predict a bright future for technology,
but responsibly urge a critical exploration of the darker,
murkier contours, where human exploitation, greed,
incompetence, and lack of deference to the rules of law expose
the vulnerabilities of law, science and modern technology.
Readers will note the subtle, but evidenced themes relating
to the challenges of biotechnology and risk in a global age; the
call for recalibrating what disclosures should be demanded in
an era where biotechnological advancements can at times
incentivize unethical conduct that exploits the vulnerable, and
the challenge in defining personhood and biology as the
technological state and the products it produces has morphed.
And in that evolution, biologics can have synthetic twins and
companies can be persons.
Scholars participating in this special issue observe that we
live in a global community with increasingly narrow, rather
than thick borders. They note that science all the more breaks
down these barriers, but so do diseases and illnesses. James
Hodge, for example, reminds us of the pitfalls when
international collaboration and cooperation fails.
In “Global Legal Triage in Response to the 2009 H1N1
Outbreak,” Hodge reminds us that the disparate response to
the virus that threatened possible international devastation
was incoherent and incongruent at best. Despite WHO
guidelines, “proven public health interventions were negated,”
and as a result, “human rights abuses arose,” compounded by

GOODWIN INTRO_FINAL (DO NOT DELETE)

2010]

RISING STARS

6/10/2010 2:30 PM

565

the spread of the influenza and devastating economic impacts.1
Hodge highlights a new era in law and science, where borders
are permeable and not static, solid, and impenetrable.
In this new era, where the luxury of international travel is
frequent and afforded by more people, the probability of
spreading viruses increases. The danger is that communicable
diseases do not recognize borders and customs. How to combat
that? Hodge emphasizes that with the luxury of travel come
certain governmental challenges and responsibilities. For this
reason, he warns that tepid response to international protocols
to prevent the spread of deadly viruses will likely lead to
economic and health disasters. His intuition is yet to be fully
tested, but ample evidence from the spread of H1N1 helps to
bolster his claim.
At the intersection of technology and law collisions occur,
and far too often race and gender operate at those locations.2
Such was the case of Henrietta Lacks and the exploitation of
her cell line. Largely forgotten or overlooked in the annals of
medicine, Lacks’ story was first visited by journalist and
author, Harriet Washington, in articles and her award winning
work, Medical Apartheid: The Dark History of Medical
Experimentation on Black Americans from Colonial Times to
the Present. More recently, Rebecca Skloot takes up the charge
to resurrect Lacks’ important contributions to science, in The
Immortal Life of Henrietta Lacks, and Gail Javitt interrogates
that work and reflects on the rule of law and respect for
participants in tissue-based research. Javitt’s observations are
part of this special issue.
Javitt notes that in few cases has there been one to “singlehandedly” offer a “scientific paradigm shift.”3 But that
paradigm shift, and the underlying motivations for the use of
Ms. Lacks’ cell line, and the misinformation and lack of
information provided to Lacks and her family paints a dark
picture on the complicated canvass of American scientific
history. At a time when African Americans were refused
services at many hospitals across the United States,
1. James G. Hodge, Global Legal Triage in Response to the 2009 H1N1
Outbreak, 11 MINN. J. L. SCI. & TECH. 599, 627 (2010).
2. See e.g., Michele Goodwin and Song Richardson, Patient Negligence,
72 DUKE J. OF L. & CONTEMPORARY PROBLEMS 223 (2010).
3. Gail Javitt, Why Not Take All of Me? Reflections on The Immortal Life
of Henrietta Lacks and the Status of Participants in Research Using Human
Specimens, 11 MINN. J. L. SCI. & TECH. 713, 713 (2010).
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researchers discovered a treasure trove in her cell line that
would change the manner in which pharmaceutical
developments occur and how biological research is conducted
for decades to come. Scientific researchers’ failure to provide a
meaningful disclosure to Lacks’ family and obtain appropriate
consent has caused a revisit of her case.
Lacks’ valuable cell-line serves as the base of numerous
life-saving vaccines and other treatments. But to tell Ms. Lacks’
story absent of the context of her times, and her status is to
ignore the conditions under which scientific research becomes
captive to coercion, exploitation and greed. Javitt, like her
colleagues in this special issue, sketches a cautionary portrait
of scientific research involving human subjects and their
tissues. She argues that the “use of cells and tissues for
research brings with it myriad legal and ethical questions.”4
For example, to whom does the proprietary interest belong?
Should ownership of a cell-line belong to anyone at all or be
part of a public commons?
Javitt points out that important social and legal
consequences result no matter how the questions are answered.
More importantly is that the questions are answered, and that
patient autonomy and dignity are honored and respected
legally, medically, and ethically in medical tissue research. At
the heart of her article are a set of urgent questions, including
an inquiry as to what should govern “the voluntary provision of
tissues by patient groups to researchers solely for the purpose
of identifying the cause of their disease . . . .”5 Recent court
cases make similar inquiries.6 Unfortunately, as Javitt notes,
the judicial treatment of these issues is often mired in
formalism, “in the service of what sometimes appear to be
preordained policy goals.”7 For Javitt policy questions
regarding the dignified use of human tissue for research
purposes cannot be answered in isolation, but rather, must
engage the public if trust is to be gained. As important, she
offers that “new federal legislation that establishes
prospectively clear, uniform terms of engagement between the
three parties to the tissue research enterprise,” will be needed.
4. Id. at 714.
5. Id. at 714.
6. See Michele Goodwin, Formalism and the Legal Status of Body Parts
26 U. CHI. LEGAL F. 317, 317–88 (2005).
7. Javitt, supra note 3, at 715.
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In synergistic fashion, Anne Drapkin Lyerly, also promotes
the use of law to temper the excesses of innovative
technologies. In Marking the Fine Line: Ethics and the
Regulation of Innovative Technologies in Human Reproduction,
Lyerly argues that, “far less attention has been directed at the
regulation of research—of oversight for the process of moving
from bench to bedside, innovation to practice,” of assisted
reproductive technologies. Like Javitt, Lyerly observes the
importance of critiquing law and status in context. In this case,
the author turns her attention to mothers, their offspring, and
the lack regulation in the field of assisted reproductive
technology (ART).
Lyerly unpacks a view of assisted reproductive technology
overlooked in the media accounts of Nadya Suleman, the
California mother that gave birth to octuplets after aggressive
hormone therapies and the implantation of multiple embryos,
or the case of Kate Gosselin, the celebrity-mother of eight.
Rather, Lyerly’s pragmatic study of the ethics and regulations
of ART is concerned “about [the] safe and ethical provision of
reproductive medicine in the 21st century,” and with that, “the
role of regulation of this process.”8
Animating Lyerly’s concern in this issue, are health and
safety considerations for the babies born from ART. When ART
is more experiment than practice, vulnerable, less-informed
patients, may become the unwitting subjects of scientific
research. Lyerly draws readers’ attention to intracytoplasmic
sperm injection (ICSI), a special reproductive technique that
remains at the center of some controversy.
Lyerly’s provocative work attempts to “pry apart”
reproductive innovations that deserve greater legal scrutiny.
She argues that while “new techniques may provide relief of
the suffering caused by infertility and the birth of children with
preventable disabilities,” such relief has also “ushered in
problems with its progress.”9 Lyerly’s intuition that innovation
is at times blurred with experimentation, serves as an
important intellectual guidepost for scholars and policy-makers
concerned about promoting biotechnology, while also protecting
the public from harm.

8. Anne Drapkin Lyerly, Marking the Fine Line: Ethics and the
Regulation of Innovative Technologies in Human Reproduction, 11 MINN. J. L.
SCI. & TECH. 685, 687 (2010).
9. Id. at 712.
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In matters of technology, these rising stars emphasize the
importance of access to information and researcher disclosure,
as an important component of the legal and ethical monitoring
processes. This important theme is picked up in Vardit
Ravitsky’s informative article, “Knowing Where You Came
From”: The Rights of Donor-Conceived Individuals and the
Meaning of Genetic Relatedness.” Such thematic threads also
appear in Braverman’s article, also published in this issue.
Ravitsky’s article adds her voice to the growing chorus
interrogating what disclosure means in the context of donorassisted births. Should children have a right to know their
genetic parents? The normative questions driving her project
emerge at multiple technological intersections: the use of
technology to conceive, the use of third parties in that process,
and social networking. At that unique intersection, young
adults are driven to find answers to their genetic mysteries.
Ravitsky suggests that part of what compels this desire “to
know” is the psychological distress experienced in “not
knowing.” For this reason, many donor-conceived teenagers and
adults have taken on the charge to learn their origins.
But the legal and ethical issues arising from the desire to
know are not well-settled—if at all. Indeed, as Ravitsky
suggests, “most fertility experts did not anticipate this
outcome. They focused on their patients, helping them create
the families they desired while perceiving the donor as a mere
means in the process.”10 Thus, the interests, rights, and
entitlements of donor-conceived offspring were largely ignored,
not only by doctors and lawyers in the ART fields, but also the
coordinating parents. Neither did state or federal legislatures
enter this fray to help define the contours of privacy rights in
the ART domain.
Further complicating this space are the conflicting
information disclosure interests between ART parents, genetic
parents, and their mutual offspring. A child might want to
know her genetic heritage, but ART and genetic parents may
desire constraint—and for differing reasons. As Ravitsky
rightly notes, at least in the cases of genetic parents, the
“trend” to avoid disclosure, “was maintained because most

10. Vardit Ravitsky, “Knowing Where You Come From”: The Rights of
Donor-Conceived Individuals and the Meaning of Genetic Relatedness, 11
MINN. J. L. SCI. & TECH. 665, 665 (2010).
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donors wish to remain anonymous and have no intention of
establishing a relationship with offspring, and most parents
choose to keep the circumstances of conception secret.”11
However, in an era where the interests of donor-conceived
children have come to the forefront, prospective ART parents
and the service providers they use are confronted with pressing
questions (and very active internet campaigns) about identity
disclosure. And the underlying motivations for urging a better
disclosure regime vary from medical, psychological, and genetic
concerns to a desire to avoid mistaken family building among
individuals who might be genetic siblings or cousins.
In the United States, donor identity is not regulated by
state or federal law. Indeed, in most countries, the norm
remains to protect donor anonymity, despite the fact that,
“donor identity is gathering momentum as a growing number of
countries are adopting laws and regulations banning
anonymity.”12 For Ravitsky the important issue at hand is how
these debates are framed and what is at stake in “knowing.”
The effort is to avoid conflating all interests in ART disclosure
as being equal or mutual, which are important lessons in law,
science and medicine.
Identity animates a third theme in this special issue
devoted to rising stars in law, science, medicine, and
technology. In a final thematic forage, both Andrea Matwyshyn
and Andrew Torrance urge the reconsideration of what the
biological means in an expanding biotechnological era. In a
brilliantly written article, “Corporate Cyborgs and Technology
Risks,” Matwyshyn contemplates a rising future where
corporations increasingly take ownership of a personhood
identity, but are in fact less human than ever before. Her work
is not one of science fiction, but a critical analysis about
corporate identity and the roles of law in promoting and
harnessing technology.
She writes, “the law has long treated corporations as
persons with rights, and it continues to expand this
treatment.”13 And with this, she evaluates that the “practical
differentiation between human persons and corporate persons
grows tenuous in many respects to the outside world,” despite

11. Id. at 665–66.
12. Id. at 666.
13. Andrea M. Matwyshyn, Corporate Cyborgs and Technology Risks, 11
MINN. J. L. SCI. & TECH. 573, 573 (2010).
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the fact that corporations are becoming “less human.” In an era
of corporate downsizing, corporations rely less on human power
and brain trust than information systems with external
humanization components. To Matwyshyn this morphing of
“human-machine identity” risks a broad acceptance of
“overzealous technology adoption” without critical auditing,
monitoring, and where necessary disciplinary protocols.
Matwyshyn argues that these incongruent forces—a more
deeply humanized status of corporate identity married to far
less human interaction demands new legal considerations. She
argues that this contradiction and “shift has carried with it
technology driven risks to both individual entities and the
economy as a whole.”14 Drawing from the securities industry as
a case study of “cyborg” transformations, she critically
examines the landmines that plagued securities markets in the
1960s and 70s and the crisis point at which the SEC
intervened. In forecasting a similar future for companies at the
forefront of various technologies, she urges an ex ante response.
The recent Gulf oil spill and the lack of precautionary measures
to contain that devastation adds urgency to her analysis.
Matwyshyn calls for an information accountability regime.
She argues quite persuasively for internal and external
corporate oversight “that more effectively blends” multiple legal
regimes. Her project is ambitious, calling for the cross
fertilization of corporate, securities, contract, intellectual
property, tort and criminal law regimes to proactively protect
our biotechnological futures and possibilities. Matwyshyn’s
project provides a platform for new policy leadership on
corporate accountability in a biotech age.
Most fitting, perhaps, is to conclude these introductory
comments with a reflection on our final Rising Stars author,
Andrew Torrance, and his contribution to this special issue:
“Synthesizing Law For Synthetic Biology.” Torrance’s work
epitomizes scholarship at the intersections of medicine, law,
science, and technology, empirically and theoretically. His
contribution to this issue builds on a nuanced and developing
body of work that aims to effect paradigm shifts in biological
sciences. Torrance, like Matwyshyn, hopes to incorporate
standardizations and innovative monitoring and auditing
mechanisms into the biological sciences. Both scholars attempt
14. Id.
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to borrow from domains that might offer contoured and tested
approaches to counteract actual, perceived, and possible
unbridled and unregulated technologies.
Torrance takes up the case of synthetic biologics, such as
synthetic DNA, with a concern about the ways in which a
perceived ethos of openness in the industries that create these
products could easily give way to less democracy and openness
in the field. He points to the proprietary restrictions resulting
from “closed” intellectual property as an example of legal risk
and uncertainty. The challenge of course for those like Torrance
who might wish this technology to be “open” to others is that
synthetic forms are not “natural.” By definition as he concedes,
“synthetic DNA sequences are likely more easily patentable
and copyrightable than are DNA sequences derived from
natural sources.”15 Torrance ultimately comes to the conclusion
that runs through this special issue: collaboration, cooperation,
and new legal frameworks must be developed to govern the
legal relationships between biotech developers and the
contributors and users they serve.
CONCLUSION
In deciding to host a special issue dedicated to the
scholarship of “rising stars” my colleagues and I reflected on
the importance and value of elevating voices that deserve a
platform. These authors contribute to a broad and rich
literature at the intersections of law, medicine, science, and
technology. Their insights illuminate gaps in current legal
regulation of biotechnologies, and yet offer creative, innovative
frameworks for addressing 21st century challenges at the heart
of law and science.
Their works remind us that at the important intersection
of law, science, and technological pioneering, social
responsibility and accountability to the public must not be lost
or bartered away. And with scientific achievements come
responsibilities—sometimes unanticipated. These scholars’
nuanced approaches to challenging issues at the intersections
will provide for an enriched and engaging dialogue for years to
come.

15. Andrew W. Torrance, Synthesizing Law for Synthetic Biology, 11
MINN. J. L. SCI. & TECH. 629, 664 (2010).

